Keck School Faculty

Heinz-Josef Lenz

Heinz-Josef Lenz

Professor of Medicine
J. Terrence Lanni Chair in Gastrointestinal Cancer Research
Co-Director, USC Center for Molecular Pathway and Drug Discovery
Co-Director of the USC Norris Center for Cancer Drug Development
Medicine
NOR 3456 Health Sciences Campus Los Angeles

Western Society of Clinical Investigation: Outstanding Investigator Award, 2016

The WunderGlo Foundation: 1st Annual Cancer Warrior Award, 2012

USC: Bob Chandler Courage Award, 2003

2003 Annual Retreat on Cancer Research: The Gallo Award, 2003

Conquer Cancer Foundation: ASCO Career Development Award, 1995-1998

Conquer Cancer Foundation: ASCO Young Investigator Award, 1994

Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials Eur J Cancer. 2022 Sep; 172:22-30. . View in PubMed

Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405 Int J Cancer. 2022 Jul 29. . View in PubMed

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 Ann Oncol. 2022 Jun 25. . View in PubMed

Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11) ESMO Open. 2022 Jun; 7(3):100512. . View in PubMed

Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial Clin Colorectal Cancer. 2022 09; 21(3):259-266. . View in PubMed

Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? Br J Cancer. 2022 09; 127(5):957-967.. View in PubMed

Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets Oncogene. 2022 06; 41(26):3455-3460. . View in PubMed

Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis J Geriatr Oncol. 2022 05; 13(4):469-479. . View in PubMed

Prognostic utility of self-reported sarcopenia (SARC-F) in the Multiethnic Cohort J Cachexia Sarcopenia Muscle. 2022 04; 13(2):987-1002. . View in PubMed

Impacts of the SARS-CoV-2 Pandemic on Young Adult Colorectal Cancer Survivors J Adolesc Young Adult Oncol. 2022 04; 11(2):229-233. . View in PubMed

Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer = 70 years Eur J Cancer. 2022 03; 163:1-15. . View in PubMed

Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer Br J Cancer. 2022 01; 126(1):72-78. . View in PubMed

Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer Oncogene. 2022 01; 41(2):260-267. . View in PubMed

Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers Mol Cancer Ther. 2022 01; 21(1):227-236. . View in PubMed

Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications J Natl Cancer Inst. 2022 02 07; 114(2):271-279. . View in PubMed

Fertility Preservation Discussions Between Young Adult Rectal Cancer Survivors and Their Providers: Sex-Specific Prevalence and Correlates Oncologist. 2022 07 05; 27(7):579-586. . View in PubMed

Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405 J Natl Cancer Inst. 2022 03 08; 114(3):427-435. . View in PubMed

Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes Mol Ther. 2022 09 07; 30(9):3066-3077. . View in PubMed

Reprogramming CBX8-PRC1 function with a positive allosteric modulatorCell Chem Biol. 2022 04 21; 29(4):555-571. e11. . View in PubMed

Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer Clin Cancer Res. 2022 05 02; 28(9):1863-1870. . View in PubMed

Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab Clin Cancer Res. 2022 04 14; 28(8):1690-1700. . View in PubMed

Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance) Clin Cancer Res. 2022 07 01; 28(13):2779-2788. . View in PubMed

fdrci: FDR confidence interval selection and adjustment for large-scale hypothesis testing Bioinform Adv. 2022; 2(1):vbac047. . View in PubMed

Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens Int J Cancer. 2022 01 15; 150(2):279-289. . View in PubMed

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial JAMA Netw Open. 2022 02 01; 5(2):e2149040. . View in PubMed

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study J Clin Oncol. 2022 01 10; 40(2):161-170. . View in PubMed

Evaluating the impact of age on immune checkpoint therapy biomarkers Cell Rep. 2021 Nov 16; 37(7):110033. . View in PubMed

Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients NPJ Precis Oncol. 2021 Oct 27; 5(1):95. . View in PubMed

Molecular characterization of squamous cell carcinoma of the anal canal J Gastrointest Oncol. 2021 Oct; 12(5):2423-2437. . View in PubMed

Clinical Significance of Circulating Tumor Cell Induced Epithelial-Mesenchymal Transition in Patients with Metastatic Colorectal Cancer by Single-Cell RNA-Sequencing Cancers (Basel). 2021 Sep 28; 13(19). . View in PubMed

Time from Diagnosis and Correlates of Health-Related Quality of Life among Young Adult Colorectal Cancer Survivors Cancers (Basel). 2021 Aug 11; 13(16). . View in PubMed

Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer J Natl Cancer Inst. 2021 Jun 01. . View in PubMed

Human colorectal cancer-on-chip model to study the microenvironmental influence on early metastatic spread iScience. 2021 May 21; 24(5):102509. . View in PubMed

Correction to: KSR1 regulates BRCA1 degradation and inhibits breast cancer growth Oncogene. 2021 May; 40(19):3473. . View in PubMed

Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients Cancer Genomics Proteomics. 2021 May-Jun; 18(3):317-324. . View in PubMed

Human-specific polymorphic pseudogenization of SIGLEC12 protects against advanced cancer progression FASEB Bioadv. 2021 Feb; 3(2):69-82. . View in PubMed

VprBP directs epigenetic gene silencing through histone H2A phosphorylation in colon cancer Mol Oncol. 2021 10; 15(10):2801-2817. . View in PubMed

Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study Eur J Cancer. 2021 09; 155:73-84. . View in PubMed

Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer Oncogene. 2021 07; 40(30):4894-4905. . View in PubMed

Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy Ann Oncol. 2021 07; 32(7):906-916. . View in PubMed

Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial Oncologist. 2021 07; 26(7):610-618. . View in PubMed

Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879 Invest New Drugs. 2021 06; 39(3):812-820. . View in PubMed

RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC Mol Cancer Ther. 2021 06; 20(6):1153-1160. . View in PubMed

Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer Eur J Cancer. 2021 06; 150:133-142. . View in PubMed

Novel Genomic Differences in Cell-Free Circulating DNA Profiles of Young- Versus Older-Onset Colorectal Cancer J Adolesc Young Adult Oncol. 2021 06; 10(3):336-341. . View in PubMed

Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer Pharmacogenomics J. 2021 06; 21(3):285-295. . View in PubMed

Clocking cancer: the circadian clock as a target in cancer therapy Oncogene. 2021 05; 40(18):3187-3200. . View in PubMed

A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors Cancer Chemother Pharmacol. 2021 04; 87(4):525-532. . View in PubMed

Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1Clin Colorectal Cancer. 2021 03; 20(1):84-95. e8. . View in PubMed

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer Oncologist. 2021 02; 26(2):e261-e269. . View in PubMed

IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405 JNCI Cancer Spectr. 2021 02; 5(1). . View in PubMed

Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer Pharmacogenet Genomics. 2021 01; 31(1):10-16. . View in PubMed

Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance) Clin Cancer Res. 2021 01 01; 27(1):267-275. . View in PubMed

Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer Clin Cancer Res. 2021 02 15; 27(4):1174-1183. . View in PubMed

Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes Sci Rep. 2021 03 11; 11(1):5639. . View in PubMed

Evaluating the impact of age on immune checkpoint therapy biomarkers Cell Rep. 2021 08 24; 36(8):109599. . View in PubMed

The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer Clin Cancer Res. 2021 06 01; 27(11):3234-3242. . View in PubMed

Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931) Cancer. 2021 10 15; 127(20):3801-3808. . View in PubMed

BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database J Natl Cancer Inst. 2021 10 01; 113(10):1386-1395. . View in PubMed

Microsatellite Stable Colorectal Liver Metastases-Understanding the Mechanisms of Immune Resistance JAMA Netw Open. 2021 08 02; 4(8):e2119025. . View in PubMed

Site-specific antibody-drug conjugates with variable drug-to-antibody-ratios for AML therapy J Control Release. 2021 08 10; 336:433-442. . View in PubMed

The Emergence of Baricitinib: A Story of Tortoises Versus Hares Clin Infect Dis. 2021 04 08; 72(7):1251-1252. . View in PubMed

Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS Cells. 2021 05 21; 10(6). . View in PubMed

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients Sci Rep. 2021 06 09; 11(1):12191. . View in PubMed

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 Autophagy. 2021 Jan; 17(1):1-382. . View in PubMed

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406) J Clin Oncol. 2021 02 01; 39(4):285-294. . View in PubMed

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors Clin Cancer Res. 2021 05 15; 27(10):2723-2733. . View in PubMed

Imaging-Based Machine Learning Analysis of Patient-Derived Tumor Organoid Drug Response Front Oncol. 2021; 11:771173. . View in PubMed

Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer JAMA Oncol. 2020 Nov 01; 6(11):1713-1721. . View in PubMed

Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients Cancers (Basel). 2020 Oct 13; 12(10). . View in PubMed

A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013 J Patient Rep Outcomes. 2020 Jul 08; 4(1):54. . View in PubMed

Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial Cancers (Basel). 2020 Jun 30; 12(7). . View in PubMed

Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma J Surg Oncol. 2020 Jun; 121(8):1320-1328. . View in PubMed

Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405 JNCI Cancer Spectr. 2020 Jun; 4(3):pkaa024. . View in PubMed

Anti-EGFR Therapy Induces EGF Secretion by Cancer-Associated Fibroblasts to Confer Colorectal Cancer Chemoresistance Cancers (Basel). 2020 May 28; 12(6). . View in PubMed

WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype Cancers (Basel). 2020 May 22; 12(5). . View in PubMed

How we treat left-sided vs right-sided colon cancer Clin Adv Hematol Oncol. 2020 May; 18(5):253-257. . View in PubMed

Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance) JNCI Cancer Spectr. 2020 Feb; 4(1):pkz078. . View in PubMed

Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib Cancer Sci. 2020 Feb; 111(2):441-450. . View in PubMed

Molecular Characterization of Appendiceal Goblet Cell Carcinoid Mol Cancer Ther. 2020 12; 19(12):2634-2640. . View in PubMed

All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide JCO Oncol Pract. 2020 12; 16(12):793-798. . View in PubMed

ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper Nat Rev Clin Oncol. 2020 12; 17(12):757-770. . View in PubMed

Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer Oncologist. 2020 12; 25(12):e1879-e1885. . View in PubMed

The impact of ARID1A mutation on molecular characteristics in colorectal cancer Eur J Cancer. 2020 11; 140:119-129. . View in PubMed

Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer J Immunother Cancer. 2020 11; 8(2). . View in PubMed

The structure-function relationship of oncogenic LMTK3 Sci Adv. 2020 11; 6(46). . View in PubMed

Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma ESMO Open. 2020 11; 5(6):e000942. . View in PubMed

Risk of Persistent Opioid Use following Major Surgery in Matched Samples of Patients with and without Cancer Cancer Epidemiol Biomarkers Prev. 2020 11; 29(11):2126-2133. . View in PubMed

Reply to the letter to the editor 'Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil' by Colloca et al Ann Oncol. 2020 08; 31(8):1085-1087. . View in PubMed

Molecular profile of BRCA-mutated biliary tract cancers ESMO Open. 2020 06; 5(3):e000682. . View in PubMed

Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019) Eur J Surg Oncol. 2020 06; 46(6):955-966. . View in PubMed

Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases Sci Adv. 2020 06; 6(23):eaba6752. . View in PubMed

A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer Invest New Drugs. 2020 06; 38(3):821-830. . View in PubMed

Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer Oncologist. 2020 05; 25(5):404-413. . View in PubMed

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies J Immunother Cancer. 2020 05; 8(1). . View in PubMed

A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials Eur J Cancer. 2020 05; 131:89-97. . View in PubMed

Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases Br J Cancer. 2020 05; 122(10):1518-1524. . View in PubMed

Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset CancerGastroenterology. 2020 04; 158(5):1274-1286. e12. . View in PubMed

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials Ann Oncol. 2020 01; 31(1):88-95. . View in PubMed

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma Clin Cancer Res. 2020 02 15; 26(4):846-854. . View in PubMed

Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201 J Clin Oncol. 2020 02 10; 38(5):472-479. . View in PubMed

Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) Clin Cancer Res. 2020 11 15; 26(22):5943-5951. . View in PubMed

Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer Clin Cancer Res. 2020 10 15; 26(20):5348-5357. . View in PubMed

Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome Clin Cancer Res. 2020 09 15; 26(18):4756-4766. . View in PubMed

12-Chemokine signature, a predictor of tumor recurrence in colorectal cancer Int J Cancer. 2020 07 15; 147(2):532-541. . View in PubMed

Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer Sci Rep. 2020 06 17; 10(1):9778. . View in PubMed

Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors Int J Cancer. 2020 11 15; 147(10):2948-2956. . View in PubMed

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer PLoS One. 2020; 15(9):e0239439. . View in PubMed

Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial JAMA Netw Open. 2020 10 01; 3(10):e2023500. . View in PubMed

Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy Mol Ther. 2020 02 05; 28(2):536-547. . View in PubMed

Partition: a surjective mapping approach for dimensionality reduction Bioinformatics. 2020 02 01; 36(3):676-681. . View in PubMed

Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer Oncotarget. 2019 Dec 17; 10(66):7016-7030. . View in PubMed

Molecular insight of regorafenib treatment for colorectal cancer Cancer Treat Rev. 2019 Dec; 81:101912. . View in PubMed

Publisher Correction: Shared heritability and functional enrichment across six solid cancers Nat Commun. 2019 Sep 23; 10(1):4386. . View in PubMed

Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A EBioMedicine. 2019 Jul; 45:139-154. . View in PubMed

The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective Am J Health Syst Pharm. 2019 Feb 21; 76(6):339-348. . View in PubMed

B cell and B cell-related pathways for novel cancer treatments Cancer Treat Rev. 2019 Feb; 73:10-19. . View in PubMed

Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 AnalysesClin Colorectal Cancer. 2019 12; 18(4):269-279. e5. . View in PubMed

Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial Cancer Chemother Pharmacol. 2019 12; 84(6):1201-1208. . View in PubMed

Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer Oncologist. 2019 11; 24(11):1453-1461. . View in PubMed

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction Br J Clin Pharmacol. 2019 11; 85(11):2499-2511. . View in PubMed

A Multicenter Comparison of Complementary and Alternative Medicine (CAM) Discussions in Oncology Care: The Role of Time, Patient-Centeredness, and Practice Context Oncologist. 2019 11; 24(11):e1180-e1189. . View in PubMed

Novel Circulating Tumor Cell Assay for Detection of Colorectal Adenomas and Cancer Clin Transl Gastroenterol. 2019 10; 10(10):e00088. . View in PubMed

Conversations About Financial Issues in Routine Oncology Practices: A Multicenter Study J Oncol Pract. 2019 08; 15(8):e690-e703. . View in PubMed

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study Lancet Oncol. 2019 08; 20(8):1070-1082. . View in PubMed

Quantitative evidence for early metastatic seeding in colorectal cancer Nat Genet. 2019 07; 51(7):1113-1122. . View in PubMed

Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM) Oncologist. 2019 07; 24(7):921-932. . View in PubMed

The current state of molecular testing in the treatment of patients with solid tumors, 2019 CA Cancer J Clin. 2019 07; 69(4):305-343. . View in PubMed

Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3 Eur J Cancer. 2019 04; 111:138-147. . View in PubMed

Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy Clin Colorectal Cancer. 2019 03; 18(1):e8-e19. . View in PubMed

Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors Oncologist. 2019 03; 24(3):319-326. . View in PubMed

Safety and Tolerability of c-MET Inhibitors in Cancer Drug Saf. 2019 02; 42(2):211-233. . View in PubMed

Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial Eur J Cancer. 2019 01; 107:100-114. . View in PubMed

Reply to SSorscher. J Clin Oncol. 2019 09 01; 37(25):2291-2293. . View in PubMed

AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3 Int J Cancer. 2019 10 15; 145(8):2082-2090. . View in PubMed

A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors Int J Cancer. 2019 11 01; 145(9):2450-2458. . View in PubMed

Novel Common Genetic Susceptibility Loci for Colorectal Cancer J Natl Cancer Inst. 2019 02 01; 111(2):146-157. . View in PubMed

MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Clin Cancer Res. 2019 05 15; 25(10):2988-2995. . View in PubMed

Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405 J Clin Oncol. 2019 10 10; 37(29):2620-2631. . View in PubMed

Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients Int J Cancer. 2019 05 15; 144(10):2567-2577. . View in PubMed

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial Ann Oncol. 2019 11 01; 30(11):1796-1803. . View in PubMed

J Natl Cancer Inst. 2019 08 01; 111(8):754-756. . View in PubMed

Shared heritability and functional enrichment across six solid cancers Nat Commun. 2019 01 25; 10(1):431. . View in PubMed

Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer Clin Cancer Res. 2019 05 15; 25(10):3096-3103. . View in PubMed

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome J Clin Oncol. 2019 05 10; 37(14):1217-1227. . View in PubMed

Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance) Clin Cancer Res. 2019 12 15; 25(24):7497-7505. . View in PubMed

The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer Cancer Manag Res. 2019; 11:5911-5924. . View in PubMed

Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims Arch Osteoporos. 2019 07 28; 14(1):83. . View in PubMed

High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma PLoS One. 2019; 14(7):e0219469. . View in PubMed

Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance) J Clin Oncol. 2019 08 01; 37(22):1876-1885. . View in PubMed

Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives Clin Adv Hematol Oncol. 2018 Nov; 16(11):735-745. . View in PubMed

Outlooks on Epstein-Barr virus associated gastric cancer Cancer Treat Rev. 2018 May; 66:15-22. . View in PubMed

Differentiation Therapy Targeting the ß-Catenin/CBP Interaction in Pancreatic Cancer Cancers (Basel). 2018 Mar 29; 10(4). . View in PubMed

CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy Cancer Treat Rev. 2018 Feb; 63:40-47. . View in PubMed

Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation Cancer Treat Rev. 2018 Feb; 63:48-60. . View in PubMed

Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer Clin Colorectal Cancer. 2018 12; 17(4):e741-e749. . View in PubMed

Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer Mol Cancer Ther. 2018 12; 17(12):2788-2795. . View in PubMed

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer Br J Cancer. 2018 12; 119(12):1451-1455. . View in PubMed

A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer Am J Clin Oncol. 2018 12; 41(12):1193-1198. . View in PubMed

Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma Oncologist. 2018 11; 23(11):1319-1327. . View in PubMed

First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors Invest New Drugs. 2018 10; 36(5):860-868. . View in PubMed

Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study Clin Colorectal Cancer. 2018 09; 17(3):e471-e488. . View in PubMed

Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer Pharmacogenomics J. 2018 09; 18(5):623-632. . View in PubMed

Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 StudyClin Colorectal Cancer. 2018 09; 17(3):215-222. e3. . View in PubMed

Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib Clin Colorectal Cancer. 2018 06; 17(2):e395-e414. . View in PubMed

Biomarker-driven and molecular targeted therapies for colorectal cancers Semin Oncol. 2018 06; 45(3):124-132. . View in PubMed

Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers Mol Cancer Res. 2018 05; 16(5):805-812. . View in PubMed

A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma Cancer Chemother Pharmacol. 2018 05; 81(5):957-963. . View in PubMed

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours Br J Cancer. 2018 04; 118(7):938-946. . View in PubMed

Prognostic impact of FOXF1 polymorphisms in gastric cancer patients Pharmacogenomics J. 2018 04; 18(2):262-269. . View in PubMed

Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713 Clin Colorectal Cancer. 2018 03; 17(1):e121-e125. . View in PubMed

The role of tumor angiogenesis as a therapeutic target in colorectal cancer Expert Rev Anticancer Ther. 2018 03; 18(3):251-266. . View in PubMed

Colorectal cancer in 2017: Practice-changing updates in the adjuvant and metastatic setting Nat Rev Clin Oncol. 2018 02; 15(2):77-78. . View in PubMed

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer Eur J Cancer. 2018 02; 90:63-72. . View in PubMed

Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response Br J Cancer. 2018 01; 118(2):181-188. . View in PubMed

Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients Pharmacogenomics J. 2018 01; 18(1):29-34. . View in PubMed

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials Pharmacogenomics J. 2018 01; 18(1):43-48. . View in PubMed

Outlook: Immunotherapy in Gastrointestinal Carcinoma - Innovative Strategies Oncol Res Treat. 2018; 41(5):313-315. . View in PubMed

Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study Ann Oncol. 2018 09 01; 29(9):1955-1963. . View in PubMed

NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients PLoS One. 2018; 13(3):e0193640. . View in PubMed

Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives J Cancer Metastasis Treat. 2018; 4(3). . View in PubMed

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer J Clin Oncol. 2018 03 10; 36(8):773-779. . View in PubMed

Management of Advanced Small Bowel Cancer Curr Treat Options Oncol. 2018 11 05; 19(12):69. . View in PubMed

Reprogramming Exosomes as Nanoscale Controllers of Cellular Immunity J Am Chem Soc. 2018 12 05; 140(48):16413-16417. . View in PubMed

A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab Clin Cancer Res. 2018 02 15; 24(4):784-793. . View in PubMed

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells J Clin Invest. 2018 11 01; 128(11):4912-4923. . View in PubMed

DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies Oncogene. 2018 02 01; 37(5):566-577. . View in PubMed

Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions Cancer Cell Int. 2018; 18:99. . View in PubMed

Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study Clin Cancer Res. 2018 08 15; 24(16):3829-3837. . View in PubMed

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance) Clin Cancer Res. 2018 10 01; 24(19):4734-4744. . View in PubMed

Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types Biochem Biophys Res Commun. 2018 06 07; 500(3):621-625. . View in PubMed

Trends in colorectal cancer mortality in hispanics: a SEER analysis Oncotarget. 2017 Dec 12; 8(65):108771-108777. . View in PubMed

Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer Indian J Surg Oncol. 2017 Dec; 8(4):580-590. . View in PubMed

Colorectal cancer: epigenetic alterations and their clinical implications Biochim Biophys Acta Rev Cancer. 2017 Dec; 1868(2):439-448. . View in PubMed

Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer Cancer Chemother Pharmacol. 2017 Dec; 80(6):1161-1169. . View in PubMed

Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer Cancer. 2017 Nov 15; 123(22):4506-4514. . View in PubMed

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials Ann Oncol. 2017 Nov 01; 28(11):2780-2785. . View in PubMed

Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers Oncotarget. 2017 Oct 17; 8(49):86356-86368. . View in PubMed

DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer Cancer. 2017 Oct 01; 123(19):3732-3743. . View in PubMed

Mindfulness practice reduces cortisol blunting during chemotherapy: A randomized controlled study of colorectal cancer patients Cancer. 2017 Aug 15; 123(16):3088-3096. . View in PubMed

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials Ann Oncol. 2017 Aug 01; 28(8):1713-1729. . View in PubMed

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers Clin Cancer Res. 2017 Jul 15; 23(14):3657-3666. . View in PubMed

New perspectives for colorectal cancer Oncotarget. 2017 Jun 27; 8(26):41782-41783. . View in PubMed

Five-year mortality in patients treated for severe community-acquired pneumonia - a retrospective study Acta Anaesthesiol Scand. 2017 Apr; 61(4):418-426. . View in PubMed

What roles do colon stem cells and gap junctions play in the left and right location of origin of colorectal cancers? J Cell Commun Signal. 2017 Mar; 11(1):79-87.. View in PubMed

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials JAMA Oncol. 2017 Feb 01; 3(2):194-201. . View in PubMed

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy Pharmacogenomics J. 2017 12; 17(6):543-550. . View in PubMed

Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer Pharmacogenomics J. 2017 12; 17(6):528-534. . View in PubMed

Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis Pharmacogenomics J. 2017 12; 17(6):535-542. . View in PubMed

Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer Eur J Cancer. 2017 11; 86:197-206. . View in PubMed

Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes Eur J Cancer. 2017 10; 84:69-80. . View in PubMed

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study Lancet Oncol. 2017 09; 18(9):1182-1191. . View in PubMed

What We Know About Stage II and III Colon Cancer: It's Still Not Enough Target Oncol. 2017 06; 12(3):265-275. . View in PubMed

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer Cancer Discov. 2017 06; 7(6):610-619. . View in PubMed

Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials Eur J Cancer. 2017 05; 77:13-20. . View in PubMed

A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803 Oncologist. 2017 01; 22(1):107-114. . View in PubMed

Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer Pharmacogenomics J. 2017 01; 17(1):36-41. . View in PubMed

Genetic variants associated with colorectal brain metastases susceptibility and survival Pharmacogenomics J. 2017 01; 17(1):29-35. . View in PubMed

Comparative effectiveness of screening strategies for colorectal cancer Cancer. 2017 05 01; 123(9):1516-1527. . View in PubMed

Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer Ann Oncol. 2017 05 01; 28(5):1015-1022. . View in PubMed

Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial Int J Cancer. 2017 07 15; 141(2):383-392. . View in PubMed

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial JAMA. 2017 06 20; 317(23):2392-2401. . View in PubMed

Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer Int J Cancer. 2017 09 15; 141(6):1222-1230. . View in PubMed

An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma Clin Cancer Res. 2016 Nov 01; 22(21):5204-5210. . View in PubMed

Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012 Oncotarget. 2016 Aug 16; 7(33):53668-53678. . View in PubMed

Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment Clin Cancer Res. 2016 Aug 15; 22(16):3999-4004. . View in PubMed

Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications Expert Rev Clin Pharmacol. 2016 Aug; 9(8):1091-108. . View in PubMed

The safety of monoclonal antibodies for treatment of colorectal cancer Expert Opin Drug Saf. 2016 Jun; 15(6):799-808. . View in PubMed

Biomarker in Colorectal Cancer Cancer J. 2016 May-Jun; 22(3):156-64. . View in PubMed

Gradual withdrawal of remifentanil infusion may prevent opioid-induced hyperalgesia Br J Anaesth. 2016 Apr; 116(4):524-30. . View in PubMed

Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer Crit Rev Oncol Hematol. 2016 Apr; 100:117-26. . View in PubMed

Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors Ann Oncol. 2016 Feb; 27(2):318-23. . View in PubMed

Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer Oncologist. 2016 Feb; 21(2):172-7. . View in PubMed

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database J Clin Oncol. 2016 Jan 10; 34(2):144-50. . View in PubMed

Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population Clin Colorectal Cancer. 2016 12; 15(4):e221-e227. . View in PubMed

Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection Mol Cancer Ther. 2016 11; 15(11):2814-2821. . View in PubMed

A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer Mol Cancer Ther. 2016 09; 15(9):2251-8. . View in PubMed

Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer Pharmacogenomics J. 2016 08; 16(4):312-9. . View in PubMed

Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab Mol Cancer Ther. 2016 07; 15(7):1740-5. . View in PubMed

Genome-wide association study of colorectal cancer in Hispanics Carcinogenesis. 2016 06; 37(6):547-556. . View in PubMed

TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy Mol Cancer Ther. 2016 06; 15(6):1405-11. . View in PubMed

Colorectal cancer: Overcoming resistance to anti-EGFR therapy - where do we stand? Nat Rev Gastroenterol Hepatol. 2016 05; 13(5):258-9.. View in PubMed

A novel antimetabolite: TAS-102 for metastatic colorectal cancer Expert Rev Clin Pharmacol. 2016; 9(3):355-65. . View in PubMed

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 ESMO Open. 2016; 1(5):e000097. . View in PubMed

Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer Cancer Biol Ther. 2016 07 02; 17(7):751-9. . View in PubMed

CDX2 as a Prognostic Biomarker in Colon Cancer N Engl J Med. 2016 06 02; 374(22):2183. . View in PubMed

Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy Clin Cancer Res. 2016 07 01; 22(13):3218-26. . View in PubMed

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer J Clin Oncol. 2015 Dec 20; 33(36):4284-92. . View in PubMed

Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials Ann Oncol. 2015 Dec; 26(12):2450-6. . View in PubMed

Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases Pharmacogenomics J. 2015 Dec; 15(6):521-9. . View in PubMed

Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor Clin Cancer Res. 2015 Nov 15; 21(22):5002-7. . View in PubMed

TAS-102, a novel antitumor agent: a review of the mechanism of action Cancer Treat Rev. 2015 Nov; 41(9):777-83. . View in PubMed

Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial Cancer Chemother Pharmacol. 2015 Nov; 76(5):897-907. . View in PubMed

Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients Thromb Res. 2015 Nov; 136(5):865-9. . View in PubMed

Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach Mol Cancer Ther. 2015 Oct; 14(10):2401-8. . View in PubMed

LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy Pharmacogenomics J. 2015 Oct; 15(5):391-6. . View in PubMed

Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer Mol Cancer Ther. 2015 Oct; 14(10):2374-81. . View in PubMed

Response J Natl Cancer Inst. 2015 Sep; 107(9). . View in PubMed

Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases Ann Oncol. 2015 Aug; 26(8):1728-33. . View in PubMed

Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy Pharmacogenomics J. 2015 Aug; 15(4):354-62. . View in PubMed

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial Lancet Oncol. 2015 Aug; 16(8):937-48. . View in PubMed

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer Eur J Cancer. 2015 Jul; 51(10):1243-52. . View in PubMed

Non-coding RNAs derived from an alternatively spliced REST transcript (REST-003) regulate breast cancer invasiveness Sci Rep. 2015 Jun 08; 5:11207. . View in PubMed

Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERa-positive advanced breast cancer Pharmacogenomics J. 2015 Jun; 15(3):235-40. . View in PubMed

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study Gut. 2015 Jun; 64(6):921-8. . View in PubMed

Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results Int J Clin Oncol. 2015 Jun; 20(3):518-24. . View in PubMed

Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases Cancer. 2015 Jun 01; 121(11):1898-905. . View in PubMed

Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer Pharmacogenomics J. 2015 Jun; 15(3):226-34. . View in PubMed

Randomized trial of TAS-102 for refractory metastatic colorectal cancer N Engl J Med. 2015 May 14; 372(20):1909-19. . View in PubMed

IL-33 activates tumor stroma to promote intestinal polyposis Proc Natl Acad Sci U S A. 2015 May 12; 112(19):E2487-96. . View in PubMed

Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors J Clin Oncol. 2015 May 10; 33(14):1551-6. . View in PubMed

Pharmacogenomics of fluorouracil -based chemotherapy toxicity Expert Opin Drug Metab Toxicol. 2015 May; 11(5):811-21. . View in PubMed

KSR1 regulates BRCA1 degradation and inhibits breast cancer growth Oncogene. 2015 Apr 16; 34(16):2103-14. . View in PubMed

Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network Curr Treat Options Oncol. 2015 Apr; 16(4):17. . View in PubMed

Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation Clin Cancer Res. 2015 Apr 01; 21(7):1583-90. . View in PubMed

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours Br J Cancer. 2015 Mar 31; 112(7):1199-205. . View in PubMed

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer J Clin Oncol. 2015 Mar 01; 33(7):692-700. . View in PubMed

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine Cancer Chemother Pharmacol. 2015 Mar; 75(3):537-46. . View in PubMed

Cost-effectiveness of genomic testing for colorectal cancer: are we there yet? Oncology (Williston Park). 2015 Mar; 29(3):183-4; 186.. View in PubMed

Primary tumor location as a prognostic factor in metastatic colorectal cancer J Natl Cancer Inst. 2015 Mar; 107(3). . View in PubMed

Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer Ann Oncol. 2015 Feb; 26(2):332-9. . View in PubMed

Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer Pharmacogenomics J. 2015 Feb; 15(1):69-76. . View in PubMed

Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work Hematol Oncol Clin North Am. 2015 Feb; 29(1):43-60. . View in PubMed

Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer Pharmacogenet Genomics. 2015 Jan; 25(1):30-7. . View in PubMed

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer Cancer Chemother Pharmacol. 2015 Jan; 75(1):17-23. . View in PubMed

Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors Br J Cancer. 2014 Dec 09; 111(12):2268-74. . View in PubMed

Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients Pharmacogenet Genomics. 2014 Dec; 24(12):588-96. . View in PubMed

Impact of sex on the survival of patients with hepatocellular carcinoma: a Surveillance, Epidemiology, and End Results analysis Cancer. 2014 Dec 01; 120(23):3707-16. . View in PubMed

Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304) Cancer. 2014 Nov 01; 120(21):3329-3337. . View in PubMed

Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent Pharmacogenet Genomics. 2014 Nov; 24(11):539-47. . View in PubMed

So much effort, so little progress? J Natl Cancer Inst. 2014 Oct; 106(10).. View in PubMed

Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727) Cancer. 2014 Oct 01; 120(19):2980-5. . View in PubMed

A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy Clin Cancer Res. 2014 Sep 01; 20(17):4499-4510. . View in PubMed

Safely targeting cancer stem cells via selective catenin coactivator antagonism Cancer Sci. 2014 Sep; 105(9):1087-92. . View in PubMed

Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer Invest New Drugs. 2014 Aug; 32(4):682-90. . View in PubMed

Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients Pharmacogenomics J. 2014 Aug; 14(4):322-7. . View in PubMed

A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer Cancer Med. 2014 Aug; 3(4):988-97. . View in PubMed

CXCR2 inhibition enhances sulindac-mediated suppression of colon cancer development Int J Cancer. 2014 Jul 01; 135(1):232-7. . View in PubMed

ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer Cell Rep. 2014 Jun 26; 7(6):1940-55. . View in PubMed

The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin ß1 Sci Signal. 2014 Jun 17; 7(330):ra58. . View in PubMed

Molecular pathways: turning proteasomal protein degradation into a unique treatment approach Clin Cancer Res. 2014 Jun 15; 20(12):3064-70. . View in PubMed

Panitumumab safety for treating colorectal cancer Expert Opin Drug Saf. 2014 Jun; 13(6):843-51. . View in PubMed

The potential of targeting Wnt/ß-catenin in colon cancer Expert Opin Ther Targets. 2014 Jun; 18(6):611-5. . View in PubMed

Standing the test of time: targeting thymidylate biosynthesis in cancer therapy Nat Rev Clin Oncol. 2014 May; 11(5):282-98. . View in PubMed

Association of common gene variants in the WNT/ß-catenin pathway with colon cancer recurrence Pharmacogenomics J. 2014 Apr; 14(2):142-50. . View in PubMed

Panitumumab : leading to better overall survival in metastatic colorectal cancer? Expert Opin Biol Ther. 2014 Apr; 14(4):535-48.. View in PubMed

Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy Pharmacogenomics J. 2014 Apr; 14(2):135-41. . View in PubMed

The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy Pharmacogenomics J. 2014 Apr; 14(2):130-4. . View in PubMed

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma Br J Cancer. 2014 Feb 18; 110(4):882-7. . View in PubMed

Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy Mol Cancer Ther. 2014 Feb; 13(2):528-39. . View in PubMed

Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients Invest New Drugs. 2014 Feb; 32(1):113-22. . View in PubMed

Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen Pharmacogenomics J. 2014 Feb; 14(1):28-34. . View in PubMed

KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies Lung Cancer. 2014 Feb; 83(2):163-7. . View in PubMed

Testing for RAS mutations in patients with metastatic colorectal cancer Clin Adv Hematol Oncol. 2014 Jan; 12(1):48-9. . View in PubMed

A small cog in a big wheel: PIK3CA mutations in colorectal cancer J Natl Cancer Inst. 2013 Dec 04; 105(23):1775-6. . View in PubMed

Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care Clin Colorectal Cancer. 2013 Dec; 12(4):275-9. . View in PubMed

Protein kinase inhibitors in metastatic colorectal cancer Let's pick patientstumorsand kinase inhibitors to piece the puzzle together! Expert Opin Pharmacother. 2013 Nov; 14(16):2203-20. . View in PubMed

Role of cyclin polymorphisms in predicting outcome of 5-fluorouracil-based chemotherapy in colorectal cancer: one piece in a complex puzzle Pharmacogenomics. 2013 Nov; 14(14):1671-4. . View in PubMed

Molecular pathways: Estrogen pathway in colorectal cancer Clin Cancer Res. 2013 Nov 01; 19(21):5842-8. . View in PubMed

Listening in on difficult conversations: an observational, multi-center investigation of real-time conversations in medical oncology BMC Cancer. 2013 Oct 04; 13:455. . View in PubMed

SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin J Urol. 2013 Oct; 190(4):1200-4. . View in PubMed

Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib) Pharmacogenomics J. 2013 Oct; 13(5):410-6. . View in PubMed

Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030) Br J Cancer. 2013 Oct 01; 109(7):1744-9. . View in PubMed

Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States Mol Cancer Ther. 2013 Oct; 12(10):2261-72. . View in PubMed

Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation Cancer. 2013 Aug 15; 119(16):3043-51. . View in PubMed

An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrence Pharmacogenomics J. 2013 Aug; 13(4):342-8. . View in PubMed

Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer Invest New Drugs. 2013 Aug; 31(4):845-57. . View in PubMed

A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors Cancer Chemother Pharmacol. 2013 Jul; 72(1):85-91. . View in PubMed

Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial Ann Oncol. 2013 Jul; 24(7):1754-1761. . View in PubMed

Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study Clin Cancer Res. 2013 Jul 01; 19(13):3631-9. . View in PubMed

MicroRNA-21 in colorectal cancer: "Just another brick in the wall"? J Natl Cancer Inst. 2013 Jun 19; 105(12):840-1.. View in PubMed

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy Pharmacogenomics J. 2013 Apr; 13(2):173-80. . View in PubMed

Markers of response for the antiangiogenic agent bevacizumab J Clin Oncol. 2013 Mar 20; 31(9):1219-30. . View in PubMed

Reply to JZhang et al. J Clin Oncol. 2013 Feb 20; 31(6):816-7. . View in PubMed

Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement HPB (Oxford). 2013 Feb; 15(2):106-15. . View in PubMed

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet. 2013 Jan 26; 381(9863):303-12. . View in PubMed

Interleukin-8 reduces post-surgical lymphedema formation by promoting lymphatic vessel regeneration Angiogenesis. 2013 Jan; 16(1):29-44. . View in PubMed

RAS mutations in colorectal cancer N Engl J Med. 2013 11 28; 369(22):2159. . View in PubMed

Assessing the in vivo efficacy of biologic antiangiogenic therapies Cancer Chemother Pharmacol. 2013 Jan; 71(1):1-12. . View in PubMed

Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab PLoS One. 2013; 8(7):e66774. . View in PubMed

Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer Clin Cancer Res. 2012 Oct 01; 18(19):5412-26. . View in PubMed

Angiogenesis-related agents in esophageal cancer Expert Opin Biol Ther. 2012 Oct; 12(10):1335-45. . View in PubMed

Targeted therapies: Cetuximab dosing by rash--is the scaling of EVEREST meaningful? Nat Rev Clin Oncol. 2012 Oct; 9(10):554-6.. View in PubMed

TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials Pharmacogenomics J. 2012 Oct; 12(5):404-11. . View in PubMed

Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers? J Hepatobiliary Pancreat Sci. 2012 Sep; 19(5):528-35.. View in PubMed

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma Invest New Drugs. 2012 Aug; 30(4):1597-606. . View in PubMed

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma Invest New Drugs. 2012 Aug; 30(4):1646-51. . View in PubMed

Influence of sex on the survival of patients with esophageal cancer J Clin Oncol. 2012 Jun 20; 30(18):2265-72. . View in PubMed

A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer Invest New Drugs. 2012 Jun; 30(3):1175-83. . View in PubMed

The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer Ann Oncol. 2012 Jun; 23(6):1455-64. . View in PubMed

The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models Mol Cancer Ther. 2012 Jun; 11(6):1353-64. . View in PubMed

Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis Br J Cancer. 2012 May 22; 106(11):1833-41. . View in PubMed

Explaining the unexplainable: EGFR antibodies in colorectal cancer J Clin Oncol. 2012 May 20; 30(15):1735-7. . View in PubMed

Targeting IL-8 in colorectal cancer Expert Opin Ther Targets. 2012 May; 16(5):491-7. . View in PubMed

Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414) J Thorac Oncol. 2012 May; 7(5):906-12. . View in PubMed

Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study Invest New Drugs. 2012 Apr; 30(2):723-8. . View in PubMed

LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome Breast Cancer Res Treat. 2012 Apr; 132(2):537-44. . View in PubMed

A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas Clin Cancer Res. 2012 Mar 15; 18(6):1726-34. . View in PubMed

Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives Scand J Gastroenterol. 2012 Mar; 47(3):325-39. . View in PubMed

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study Cancer Chemother Pharmacol. 2012 Mar; 69(3):835-43. . View in PubMed

Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer Mol Cancer Ther. 2012 Mar; 11(3):616-28. . View in PubMed

Pancreatic cancer: medical management (novel chemotherapeutics) Gastroenterol Clin North Am. 2012 Mar; 41(1):189-209. . View in PubMed

"HER majesty's a pretty nice girl but she changes from day to day" J Clin Oncol. 2012 Feb 01; 30(4):465-6; author reply 466-7. . View in PubMed

Cancer dormancy: a model of early dissemination and late cancer recurrence Clin Cancer Res. 2012 Feb 01; 18(3):645-53. . View in PubMed

A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer Mol Cancer Ther. 2012 Jan; 11(1):119-31. . View in PubMed

A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202 Cancer Chemother Pharmacol. 2011 Dec; 68(6):1595-602. . View in PubMed

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study Cancer Chemother Pharmacol. 2011 Dec; 68(6):1439-47. . View in PubMed

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer Ann Oncol. 2011 Dec; 22(12):2610-2615. . View in PubMed

S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma J Clin Oncol. 2011 Dec 01; 29(34):4555-60. . View in PubMed

Common cancer stem cell gene variants predict colon cancer recurrence Clin Cancer Res. 2011 Nov 01; 17(21):6934-43. . View in PubMed

GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients Ann Oncol. 2011 Nov; 22(11):2431-2439. . View in PubMed

Gender-related survival differences associated with polymorphic variants of estrogen receptor-ß (ERß) in patients with metastatic colon cancer Pharmacogenomics J. 2011 Oct; 11(5):375-82. . View in PubMed

A review of excision repair cross-complementation group 1 in colorectal cancer Clin Colorectal Cancer. 2011 Sep; 10(3):157-64. . View in PubMed

Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer Clin Cancer Res. 2011 Sep 01; 17(17):5783-92. . View in PubMed

Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma Int J Cancer. 2011 Sep 01; 129(5):1096-104. . View in PubMed

EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients Clin Cancer Res. 2011 Aug 01; 17(15):5161-9. . View in PubMed

Predictive molecular classifiers in colorectal cancer Semin Oncol. 2011 Aug; 38(4):576-87. . View in PubMed

Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer Nat Med. 2011 Jun; 17(6):715-9. . View in PubMed

Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity J Gastrointest Oncol. 2011 Jun; 2(2):77-84. . View in PubMed

The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models Cancer Res. 2011 May 15; 71(10):3635-48. . View in PubMed

Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer Clin Cancer Res. 2011 May 15; 17(10):3469-77. . View in PubMed

Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models Int J Cancer. 2011 May 01; 128(9):2038-49. . View in PubMed

Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer Pharmacogenomics J. 2011 Apr; 11(2):93-9. . View in PubMed

ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis Clin Cancer Res. 2011 Mar 15; 17(6):1632-40. . View in PubMed

Molecular predictors of response to antiangiogenesis therapies Cancer J. 2011 Mar-Apr; 17(2):134-41. . View in PubMed

KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter? Ann Oncol. 2011 Feb; 22(2):484-5.. View in PubMed

Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors Am J Clin Oncol. 2011 Feb; 34(1):27-31. . View in PubMed

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy Ann Oncol. 2011 Jan; 22(1):104-109. . View in PubMed

Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin Pharmacogenomics. 2011 Jan; 12(1):27-39. . View in PubMed

The colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information BMC Cancer. 2010 Dec 20; 10:687. . View in PubMed

Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients Clin Cancer Res. 2010 Nov 15; 16(22):5591-602. . View in PubMed

Molecular predictive and prognostic markers in colon cancer Cancer Treat Rev. 2010 Nov; 36(7):550-6. . View in PubMed

Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study) Anticancer Res. 2010 Oct; 30(10):4209-17. . View in PubMed

Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415) J Thorac Oncol. 2010 Sep; 5(9):1472-6. . View in PubMed

Beyond KRAS: a new approach in metastatic colorectal cancer Lancet Oncol. 2010 Aug; 11(8):706-7. . View in PubMed

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009 Ann Oncol. 2010 Jun; 21 Suppl 6:vi1-10. . View in PubMed

Integrating biomarkers into clinical decision making for colorectal cancer Clin Colorectal Cancer. 2010 Jun; 9 Suppl 1:S16-27. . View in PubMed

Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer Gastroenterology. 2010 Jun; 138(6):2163-76. . View in PubMed

Molecular markers in the treatment of metastatic colorectal cancer Cancer J. 2010 May-Jun; 16(3):262-72. . View in PubMed

Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus Ann Surg. 2010 May; 251(5):857-64. . View in PubMed

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy Cancer Chemother Pharmacol. 2010 Apr; 65(5):979-88. . View in PubMed

Colorectal cancer Lancet. 2010 Mar 20; 375(9719):1030-47. . View in PubMed

Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy Oncologist. 2010; 15(8):836-44. . View in PubMed

Molecular response prediction in multimodality treatment for adenocarcinoma of the esophagus and esophagogastric junction Recent Results Cancer Res. 2010; 182:179-91. . View in PubMed

Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma Ann Oncol. 2010 Jan; 21(1):78-86. . View in PubMed

The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38 Int J Cancer. 2009 Dec 15; 125(12):2957-69. . View in PubMed

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines BMC Med Genomics. 2009 Nov 30; 2:67. . View in PubMed

Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study Cancer Chemother Pharmacol. 2009 Nov; 64(6):1149-55. . View in PubMed

Gender disparities in metastatic colorectal cancer survival Clin Cancer Res. 2009 Oct 15; 15(20):6391-7. . View in PubMed

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer Cancer Chemother Pharmacol. 2009 Sep; 64(4):777-83. . View in PubMed

The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer Nat Genet. 2009 Aug; 41(8):882-4. . View in PubMed

Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics J Clin Oncol. 2009 Jul 20; 27(21):3540-6. . View in PubMed

Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells Int J Cancer. 2009 Jul 15; 125(2):463-73. . View in PubMed

Pharmacogenomics and -genetics in colorectal cancer Adv Drug Deliv Rev. 2009 May 20; 61(5):375-80. . View in PubMed

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124 J Clin Oncol. 2009 May 20; 27(15):2530-5. . View in PubMed

Thymidylate synthase gene variations: predictive and prognostic markers Mol Cancer Ther. 2009 May; 8(5):1000-7. . View in PubMed

Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer J Clin Oncol. 2009 May 01; 27(13):2163-9. . View in PubMed

Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer Oncologist. 2009 May; 14(5):478-88. . View in PubMed

Messenger RNA expression of COX-2 and angiogenic factors in primary colorectal cancer and corresponding liver metastasis Int J Oncol. 2009 Apr; 34(4):1147-53. . View in PubMed

Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer Pharmacogenet Genomics. 2009 Feb; 19(2):95-102. . View in PubMed

EGFR signaling and drug discovery Oncology. 2009; 77(6):400-10. . View in PubMed

Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage Nucleic Acids Res. 2009 Jan; 37(1):78-95. . View in PubMed

Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis Int J Oncol. 2008 Dec; 33(6):1257-62. . View in PubMed

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab Clin Cancer Res. 2008 Dec 01; 14(23):7884-95. . View in PubMed

KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors Clin Adv Hematol Oncol. 2008 Dec; 6(12):1-1314-6. . View in PubMed

Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab Clin Cancer Res. 2008 Nov 15; 14(22):7554-63. . View in PubMed

Clinical determinants of response to irinotecan-based therapy derived from cell line models Clin Cancer Res. 2008 Oct 15; 14(20):6647-55. . View in PubMed

Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer Ann Oncol. 2008 Oct; 19(10):1734-41. . View in PubMed

Combination chemotherapy and ALVAC-CEA/B71 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res. 2008 Aug 01; 14(15):4843-9. . View in PubMed

Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial Am J Clin Oncol. 2008 Aug; 31(4):317-22. . View in PubMed

Activity of sunitinib in patients with advanced neuroendocrine tumors J Clin Oncol. 2008 Jul 10; 26(20):3403-10. . View in PubMed

Colon cancer stem cells: a new target in the war against cancer Gastrointest Cancer Res. 2008 Jul; 2(4):203-4. . View in PubMed

Individualization of therapy for colorectal cancer based on clinical and molecular parameters Gastrointest Cancer Res. 2008 Jul; 2(4 Suppl):S38-41. . View in PubMed

Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU) Cancer Chemother Pharmacol. 2008 Jul; 62(2):363-8. . View in PubMed

Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study J Clin Oncol. 2008 May 10; 26(14):2320-6. . View in PubMed

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol. 2008 May 10; 26(14):2311-9. . View in PubMed

Accomplishments in 2007 in biologic markers for gastrointestinal cancers Gastrointest Cancer Res. 2008 May; 2(3 Suppl):S51-6. . View in PubMed

Targeting metastatic colorectal cancer in 2008: a long way from 5-FU Oncology (Williston Park). 2008 Apr 15; 22(4):456-62; discussion 462-3467-8474 passim. . View in PubMed

Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer Cancer Res. 2008 Apr 15; 68(8):3037-42. . View in PubMed

Messenger RNA expression of vascular endothelial growth factor and its receptors in primary colorectal cancer and corresponding liver metastasis Ann Surg Oncol. 2008 Apr; 15(4):1232-8. . View in PubMed

Stem cells in colon cancer Clin Colorectal Cancer. 2008 Mar; 7(2):92-8. . View in PubMed

Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer Pharmacogenet Genomics. 2008 Feb; 18(2):161-8. . View in PubMed

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group J Clin Oncol. 2008 Feb 01; 26(4):570-6. . View in PubMed

First-line combination treatment of colorectal cancer with hepatic metastases: choosing a targeted agent Cancer Treat Rev. 2008; 34 Suppl 2:S3-7. . View in PubMed

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol. 2008 Jan 01; 26(1):76-82. . View in PubMed

The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study J Thorac Oncol. 2008 Jan; 3(1):68-74. . View in PubMed

Administration of fentanyl before remifentanil-based anaesthesia has no influence on post-operative pain or analgesic consumption Acta Anaesthesiol Scand. 2008 Jan; 52(1):149-54. . View in PubMed

Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients Pharmacogenomics. 2007 Dec; 8(12):1705-13. . View in PubMed

Exploring alternative individualized treatment strategies in colorectal cancer Clin Colorectal Cancer. 2007 Dec; 7 Suppl 1:S28-36. . View in PubMed

Predictive and prognostic markers in colorectal cancer Gastrointest Cancer Res. 2007 Nov; 1(6):237-46. . View in PubMed

Molecular prognostic markers in locally advanced colon cancer Clin Colorectal Cancer. 2007 Nov; 6(10):683-90. . View in PubMed

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy J Clin Oncol. 2007 Oct 20; 25(30):4793-9. . View in PubMed

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol. 2007 Oct 10; 25(29):4557-61. . View in PubMed

Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer J Clin Oncol. 2007 Aug 20; 25(24):3726-31. . View in PubMed

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab J Clin Oncol. 2007 Aug 20; 25(24):3712-8. . View in PubMed

Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology Gastrointest Cancer Res. 2007 Jul; 1(4):146-54. . View in PubMed

Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study Clin Cancer Res. 2007 Jun 15; 13(12):3660-6. . View in PubMed

Cetuximab in the management of colorectal cancer Biologics. 2007 Jun; 1(2):77-91. . View in PubMed

Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma Clin Colorectal Cancer. 2007 May; 6(7):536-8. . View in PubMed

Management and preparedness for infusion and hypersensitivity reactions Oncologist. 2007 May; 12(5):601-9. . View in PubMed

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors Oncologist. 2007 Apr; 12(4):426-37. . View in PubMed

Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study Gynecol Oncol. 2007 Mar; 104(3):572-9. . View in PubMed

A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression Cancer Chemother Pharmacol. 2007 Mar; 59(4):549-57. . View in PubMed

ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan Drug Metab Lett. 2007 Jan; 1(1):23-30. . View in PubMed

EGFR, HER2 and VEGF pathways: validated targets for cancer treatment Drugs. 2007; 67(14):2045-75. . View in PubMed

Prognostic/Predictive molecular markers in colorectal cancer Gastrointest Cancer Res. 2007; 1(4 Suppl 2):S29-32. . View in PubMed

The continuum of care: a paradigm for the management of metastatic colorectal cancer Oncologist. 2007 Jan; 12(1):38-50. . View in PubMed

Molecular determinants of irinotecan efficacy Int J Cancer. 2006 Nov 15; 119(10):2435-42. . View in PubMed

Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer Clin Colorectal Cancer. 2006 Nov; 6(4):305-11. . View in PubMed

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines J Clin Oncol. 2006 Oct 20; 24(30):4914-21. . View in PubMed

Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer Clin Colorectal Cancer. 2006 Sep; 6(3):214-8. . View in PubMed

A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane Invest New Drugs. 2006 Sep; 24(5):441-6. . View in PubMed

Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation Pharmacogenet Genomics. 2006 Aug; 16(8):555-63. . View in PubMed

Determinants of chemosensitivity in gastric cancer Curr Opin Pharmacol. 2006 Aug; 6(4):337-44. . View in PubMed

Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab Pharmacogenet Genomics. 2006 Jul; 16(7):475-83. . View in PubMed

Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study Invest New Drugs. 2006 Jul; 24(4):335-41. . View in PubMed

Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events Oncology (Williston Park). 2006 Apr; 20(5 Suppl 2):5-13. . View in PubMed

[Predictive and prognostic factors in the neoadjuvant/adjuvant therapy of gastrointestinal tumors: wishful thinking or reality? ]. Zentralbl Chir. 2006 Apr; 131(2):148-56.. View in PubMed

Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481) J Clin Oncol. 2006 Mar 20; 24(9):1395-403. . View in PubMed

A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases Clin Cancer Res. 2006 Mar 01; 12(5):1556-63. . View in PubMed

Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe? Cancer Invest. 2006 Feb; 24(1):50-5.. View in PubMed

Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma J Clin Oncol. 2006 Feb 01; 24(4):663-7. . View in PubMed

Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial J Thorac Oncol. 2006 Feb; 1(2):126-34. . View in PubMed

Predictive and prognostic molecular markers in outcome of esophageal cancer Dis Esophagus. 2006; 19(6):425-32. . View in PubMed

Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis Invest New Drugs. 2006 Jan; 24(1):79-83. . View in PubMed

Pharmacogenomics and colorectal cancer Adv Exp Med Biol. 2006; 587:211-31. . View in PubMed

Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation Pharmacogenomics. 2006 Jan; 7(1):67-88. . View in PubMed

Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies Ann Med. 2006; 38(8):545-51. . View in PubMed

Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma Clin Colorectal Cancer. 2005 Nov; 5(4):292-4. . View in PubMed

First Amsterdam, then Bethesda, now Melbourne? J Clin Oncol. 2005 Sep 20; 23(27):6445-9.. View in PubMed

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors Clin Cancer Res. 2005 Aug 01; 11(15):5472-80. . View in PubMed

Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule Cancer Chemother Pharmacol. 2005 Jul; 56(1):75-82. . View in PubMed

Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study Clin Colorectal Cancer. 2005 Jul; 5(2):119-23. . View in PubMed

Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer Clin Colorectal Cancer. 2005 Jul; 5(2):124-31. . View in PubMed

Molecular determinants of cetuximab efficacy J Clin Oncol. 2005 May 20; 23(15):3536-44. . View in PubMed

Epidermal growth factor receptor as a target for chemotherapy Clin Colorectal Cancer. 2005 Apr; 5 Suppl 1:S19-27. . View in PubMed

Antiangiogenic agents in cancer therapy Oncology (Williston Park). 2005 Apr; 19(4 Suppl 3):17-25. . View in PubMed

Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study Gynecol Oncol. 2005 Mar; 96(3):810-7. . View in PubMed

Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial Anticancer Drugs. 2005 Mar; 16(3):317-21. . View in PubMed

Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):600-5. . View in PubMed

Angiogenesis inhibitors in the treatment of colorectal cancer Semin Oncol. 2004 Dec; 31(6 Suppl 17):10-6. . View in PubMed

Capecitabine: the new generation of fluoropyrimidines in colorectal cancer Expert Rev Anticancer Ther. 2004 Dec; 4(6):947-55. . View in PubMed

Angiogenesis as a target in colorectal cancer therapyIntroduction. Semin Oncol. 2004 Dec; 31(6 Suppl 17):1-2. . View in PubMed

Integration of novel agents in the treatment of colorectal cancer Cancer Chemother Pharmacol. 2004 Sep; 54 Suppl 1:S32-9. . View in PubMed

A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study Invest New Drugs. 2004 Aug; 22(3):335-41. . View in PubMed

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer Br J Cancer. 2004 Jul 19; 91(2):344-54. . View in PubMed

The use and development of germline polymorphisms in clinical oncology J Clin Oncol. 2004 Jul 01; 22(13):2519-21. . View in PubMed

Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy Ann N Y Acad Sci. 2004 Jun; 1022:55-60. . View in PubMed

A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels Pharmacogenetics. 2004 May; 14(5):319-27. . View in PubMed

Molecular markers in gastrointestinal cancer: targeted therapy and tailored chemotherapy Onkologie. 2004 Feb; 27(1):12-4. . View in PubMed

Tailored chemotherapy for colorectal cancer: a new approach to therapy Cancer Invest. 2004; 22(5):762-73. . View in PubMed

Pharmacogenomics and colorectal cancer Ann Oncol. 2004; 15 Suppl 4:iv173-7. . View in PubMed

The role of proteasome inhibitors in solid tumors Ann Med. 2004; 36(4):296-303. . View in PubMed

Pharmacogenetic aspects in treatment of colorectal cancer--an update Pharmacogenomics. 2003 Nov; 4(6):767-77. . View in PubMed

SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition Clin Cancer Res. 2003 Oct 15; 9(13):4772-81. . View in PubMed

Molecular predictors of treatment and outcome in colorectal cancer Curr Gastroenterol Rep. 2003 Oct; 5(5):399-405. . View in PubMed

Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study Clin Cancer Res. 2003 Oct 01; 9(12):4356-62. . View in PubMed

Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):13-5. . View in PubMed

Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer J Clin Oncol. 2003 Aug 01; 21(15):2904-11. . View in PubMed

Tailoring chemotherapy in advanced colorectal cancer Curr Opin Pharmacol. 2003 Aug; 3(4):378-85. . View in PubMed

Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group Semin Oncol. 2003 Aug; 30(4 Suppl 15):14-9. . View in PubMed

Pharmacogenomics in colorectal cancer Semin Oncol. 2003 Aug; 30(4 Suppl 15):47-53. . View in PubMed

Cyclooxygenase-2 inhibitors in colorectal cancer Semin Oncol. 2003 Jun; 30(3 Suppl 6):10-6. . View in PubMed

A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity Cancer Res. 2003 Jun 01; 63(11):2898-904. . View in PubMed

Clinical update: proteasome inhibitors in solid tumors Cancer Treat Rev. 2003 May; 29 Suppl 1:41-8. . View in PubMed

Targeted therapy and pharmacogenomic programs Cancer. 2003 Apr 15; 97(8 Suppl):2076-82. . View in PubMed

ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy Clin Adv Hematol Oncol. 2003 Mar; 1(3):162-6. . View in PubMed

Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vsrelative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products. J Clin Lab Anal. 2003; 17(5):184-94. . View in PubMed

Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer Int J Gastrointest Cancer. 2003; 34(2-3):79-86. . View in PubMed

Implications of genetic testing in the management of colorectal cancer Am J Pharmacogenomics. 2003; 3(2):73-88. . View in PubMed

Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial Cancer Chemother Pharmacol. 2002 Nov; 50(5):353-9. . View in PubMed

Clinical protocolTumor site specific phase I evaluation of safety and efficacy of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct as intervention for colorectal carcinoma metastatic to liver. Hum Gene Ther. 2002 Aug 10; 13(12):1515-37. . View in PubMed

Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer J Natl Cancer Inst. 2002 Jun 19; 94(12):936-42. . View in PubMed

The -9Ala/-9Val polymorphism in the mitochondrial targeting sequence of the manganese superoxide dismutase gene (MnSOD) is associated with age among Hispanics with colorectal carcinoma Oncol Rep. 2002 Mar-Apr; 9(2):235-8. . View in PubMed

Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer Int J Colorectal Dis. 2002 Jan; 17(1):46-9. . View in PubMed

A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer Cancer Res. 2001 Dec 15; 61(24):8654-8. . View in PubMed

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy J Clin Oncol. 2001 Dec 01; 19(23):4298-304. . View in PubMed

A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer Anticancer Res. 2001 Jul-Aug; 21(4B):3075-9. . View in PubMed

Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial Cancer Chemother Pharmacol. 2001 Jul; 48(1):22-8. . View in PubMed

Sensitive and reproducible quantitation of mucosal HIV-1 RNA and DNA viral burden in patients with detectable and undetectable plasma viral HIV-1 RNA using endoscopic biopsies J Virol Methods. 2001 Jun; 95(1-2):65-79. . View in PubMed

Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies Clin Cancer Res. 2001 Jun; 7(6):1569-76. . View in PubMed

Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach Jpn J Clin Oncol. 2001 Jun; 31(6):275-8. . View in PubMed

Determinants of prognosis and response to therapy in colorectal cancer Curr Oncol Rep. 2001 Mar; 3(2):102-8. . View in PubMed

Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy Pharmacogenomics J. 2001; 1(1):65-70. . View in PubMed

[Molecular markers as basis for chemotherapy? ]. Chirurg. 2000 Dec; 71(12):1433-9.. View in PubMed

dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer Cancer Res. 2000 Jul 01; 60(13):3493-503. . View in PubMed

Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase Clin Cancer Res. 2000 Apr; 6(4):1322-7. . View in PubMed

Phase I study of bryostatin-1 in combination with cisplatin in treating patients with metastatic or unresectable solid tumors including non small-cell lung cancer Clin Lung Cancer. 1999 Nov; 1(2):151-2. . View in PubMed

High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil Clin Cancer Res. 1998 Oct; 4(10):2371-6. . View in PubMed

Desensitization and sensitization of cells to fluoropyrimidines with different antisenses directed against thymidylate synthase messenger RNA Clin Cancer Res. 1998 Sep; 4(9):2229-36. . View in PubMed

Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity Clin Cancer Res. 1998 May; 4(5):1315-22. . View in PubMed

p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival Clin Cancer Res. 1998 May; 4(5):1243-50. . View in PubMed

p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site Clin Cancer Res. 1998 May; 4(5):1227-34. . View in PubMed

Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells Hum Gene Ther. 1998 Mar 20; 9(5):719-28. . View in PubMed

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy J Clin Oncol. 1998 Jan; 16(1):309-16. . View in PubMed

Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy Int J Radiat Oncol Biol Phys. 1997 Dec 01; 39(5):1059-68. . View in PubMed

Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin J Clin Oncol. 1997 Oct; 15(10):3223-9. . View in PubMed

High frequency of simultaneous loss of p16 and p16beta gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach Oncogene. 1997 Sep 18; 15(12):1481-8. . View in PubMed

Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy Cancer Lett. 1997 Sep 16; 118(1):29-35. . View in PubMed

Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival J Clin Oncol. 1996 Jan; 14(1):176-82. . View in PubMed

Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress Cell Growth Differ. 1995 Nov; 6(11):1405-13. . View in PubMed

Identification of mutations by RNA conformational polymorphism "bar code" analysis Genomics. 1995 Nov 01; 30(1):120-2. . View in PubMed

Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial Eur J Cancer. 1995 Jul-Aug; 31A(7-8):1306-10. . View in PubMed

Effects of cerebral TRH on intestinal water transport: role of vagal, muscarinic, and VIP pathways Am J Physiol. 1995 Jul; 269(1 Pt 1):G138-43. . View in PubMed

Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors Cancer Res. 1995 Apr 01; 55(7):1407-12. . View in PubMed

Rapid quantitative PCR for determination of relative gene expressions in tissue specimens PCR Methods Appl. 1995 Apr; 4(5):305-8. . View in PubMed

Gene amplification and multidrug resistance induced by the phosphatase-inhibitory tumor promoter, okadaic acid Carcinogenesis. 1995 Mar; 16(3):637-41. . View in PubMed

Incorporation of 5-fluorouracil into U2 and U6 snRNA inhibits mRNA precursor splicing J Biol Chem. 1994 Dec 16; 269(50):31962-8. . View in PubMed

Quantitative determination of the ratio of mutated to normal ras genes in the blood of leukemia patients by allele-specific PCR Leuk Res. 1994 Sep; 18(9):693-702. . View in PubMed

Effect of 5-fluoro- and 5-bromouracil substitution on the translation of human thymidylate synthase mRNA J Biol Chem. 1994 Jun 10; 269(23):16269-75. . View in PubMed

Detection of clonal T-cell populations in gastrointestinal lymphomas by analysis of cRNA conformational polymorphisms of rearranged T-cell-receptor-gamma genes Br J Haematol. 1994 Feb; 86(2):316-21. . View in PubMed

Quantitative analysis of folylpolyglutamate synthetase gene expression in tumor tissues by the polymerase chain reaction: marked variation of expression among leukemia patients Oncol Res. 1994; 6(7):329-35. . View in PubMed

Regulation of small intestinal and pancreaticobiliary functions by CRF Ann N Y Acad Sci. 1993 Oct 29; 697:254-9. . View in PubMed

Regulation of canine gallbladder motility by brain peptides Gastroenterology. 1993 Jun; 104(6):1678-85. . View in PubMed

Regulation of exocrine pancreatic secretion by cerebral TRH and CGRP: role of VIP, muscarinic, and adrenergic pathways Am J Physiol. 1993 Feb; 264(2 Pt 1):G237-42. . View in PubMed

Combinatorial functions of two chimeric antibodies directed to human CD4 and one directed to the alpha-chain of the human interleukin-2 receptor Gene. 1992 Nov 16; 121(2):271-8. . View in PubMed

Posttranscriptional regulation of calcitonin/CGRP gene expression Ann N Y Acad Sci. 1992 Jun 30; 657:18-35. . View in PubMed

Increased sympathetic outflow to the gut by cerebral CGRP inhibits duodenal, pancreatic, small intestinal, and biliary functions Ann N Y Acad Sci. 1992 Jun 30; 657:522-4. . View in PubMed

Detection of point mutations in human DNA by analysis of RNA conformation polymorphism(s) Nucleic Acids Res. 1992 Feb 11; 20(3):573-9. . View in PubMed

Noradrenergic inhibition of canine gallbladder contraction and murine pancreatic secretion during stress by corticotropin-releasing factor J Clin Invest. 1992 Feb; 89(2):437-43. . View in PubMed

Synthesis and functional characterization of a recombinant monoclonal antibody directed against the alpha-chain of the human interleukin-2 receptor Gene. 1991 Nov 15; 107(2):297-305. . View in PubMed

[Central regulation of gastrointestinal motility and secretion] Z Gastroenterol. 1991 Apr; 29 Suppl 3:5-9. . View in PubMed

Clinical trial of natural human lymphocyte-derived interleukin 2 in cancer patients: effects on cytokine production and suppressor cell status Biotherapy. 1991; 3(4):309-18. . View in PubMed

[Continuous infusion of natural interleukin 2 (n IL-2) in treatment of malignant diseases: phase I study] Onkologie. 1990 Dec; 13(6):429-33. . View in PubMed

Stimulation of duodenal bicarbonate secretion in conscious rats by cerebral somatostatin-28Role of neurohumoral pathways. Gastroenterology. 1990 Aug; 99(2):340-4. . View in PubMed

Brain peptides and duodenal bicarbonate Gastroenterology. 1990 Jun; 98(6):1728-30. . View in PubMed

Neurohumoral pathways mediating stress-induced inhibition of gastric acid secretion in rats Gastroenterology. 1990 Jun; 98(6):1490-2. . View in PubMed

Lymphokine release, suppressor cell generation, cell surface markers, and cytotoxic activity in cancer patients receiving natural interleukin-2 Mol Biother. 1990 Mar; 2(1):44-9. . View in PubMed

Cerebroventricular calcitonin gene-related peptide inhibits rat duodenal bicarbonate secretion by release of norepinephrine and vasopressin J Clin Invest. 1990 Jan; 85(1):25-32. . View in PubMed

Mediation of gastrointestinal stress responses by corticotropin-releasing factor Ann N Y Acad Sci. 1990; 597:81-91. . View in PubMed

Phase I-trial of clebopride, a new antiemetic, in chemotherapy--induced nausea and vomiting Eur J Clin Pharmacol. 1990; 38(5):525. . View in PubMed

Neurohumoral pathways mediating stress-induced changes in rat gastrointestinal transit Gastroenterology. 1989 Jul; 97(1):216-8. . View in PubMed

Neuroendocrine regulation of canine gastric secretion, emptying and blood flow J Neuroendocrinol. 1989 Jun 01; 1(3):163-7. . View in PubMed

Stress-induced gastrointestinal secretory and motor responses in rats are mediated by endogenous corticotropin-releasing factor Gastroenterology. 1988 Dec; 95(6):1510-7. . View in PubMed

Central nervous system effects of corticotropin-releasing factor on gastrointestinal transit in the rat Gastroenterology. 1988 Mar; 94(3):598-602. . View in PubMed

Interactions of aromatic amino acids with gastric secretagogues in humans Gastroenterology. 1988 Jan; 94(1):103-8. . View in PubMed

Increased sensitivity of gastric acid secretion to gastrin in cirrhotic patients with portacaval shunt J Clin Invest. 1987 Apr; 79(4):1120-4. . View in PubMed

Inhibition of gastric acid secretion by brain peptides in the dogRole of the autonomic nervous system and gastrin. Gastroenterology. 1986 Oct; 91(4):905-12. . View in PubMed

Intestinal phase of gastric acid secretion in humans with and without portacaval shunt Gastroenterology. 1985 Oct; 89(4):791-6. . View in PubMed

Calcitonin gene related peptide inhibits basal, pentagastrin, histamine, and bethanecol stimulated gastric acid secretion Gut. 1985 Jun; 26(6):550-5. . View in PubMed

Corticotropin-releasing factorMechanisms to inhibit gastric acid secretion in conscious dogs. J Clin Invest. 1985 Mar; 75(3):889-95. . View in PubMed

Central nervous system actions of calcitonin gene-related peptide on gastric acid secretion in the rat Gastroenterology. 1985 Feb; 88(2):539-44. . View in PubMed

CRF and gastric secretion Gastroenterology. 1985 Jan; 88(1 Pt 1):219-20. . View in PubMed

[Report of experiences in the treatment of 16 cases of severe glycoside poisoning with digitalis antibody fragments (Fab)] Z Kardiol. 1984 Feb; 73(2):113-9. . View in PubMed

Wine and five percent ethanol are potent stimulants of gastric acid secretion in humans Gastroenterology. 1983 Nov; 85(5):1082-7. . View in PubMed

[Long-term infusion-cholangiocholecystography as a routine method (author's transl)] Rontgenblatter. 1976 Nov; 29(11):533-9. . View in PubMed

[Critical evaluation and rational use of nuclear medical techniques in the diagnosis of thyroid function (author's transl)] Rontgenblatter. 1975 Dec; 28(12):569-79. . View in PubMed

[Radiologic examination of the small intestine (author's transl)] Radiologe. 1974 Sep; 14(9):393-402. . View in PubMed

[Inclusion of special radiographic methods (arteriography, venography, lymphography, scintigraphy) into disability evaluation] Chirurg. 1972 Jul; 43(7):304-14. . View in PubMed

[Poliomyelitis immunity in the federal republic of Germany in 1969II]. Zentralbl Bakteriol Orig A. 1971 Jul; 217(3):284-99. . View in PubMed

[Lithium therapy in the prevention of cyclothymic psychoses] Wien Med Wochenschr. 1971 Jun 19; 121(25):522-4. . View in PubMed

[Pattern of butterfly vestibulometry and sound threshold audiometry in labyrinth disorders] Z Laryngol Rhinol Otol. 1970 Aug; 49(8):481-9. . View in PubMed

Heinz-Josef Lenz, M.D., FACP, is the Associate Director for Clinical Research and Co-Leader of the Gastrointestinal Cancers Program at the USC Norris Comprehensive Cancer Center. Dr. Lenz is Professor of Medicine and Preventive Medicine, Section Head of GI Oncology in the Division of Medical Oncology and Co-Director of the Colorectal Center at the Keck School of Medicine of the University of Southern California.

Dr. Lenz received his medical degree from Johannes-Gutenberg Universität in Mainz, Germany, in 1985. He completed a residency in Hematology and Oncology at the University Hospital Tübingen in Germany, a clerkship in Oncology at George Washington University in Washington, DC, and a clerkship in Hematology at Beth Israel Hospital of Harvard Medical School in Boston, Massachusetts. He served subsequent fellowships in Biochemistry and Molecular Biology at the USC Norris Comprehensive Cancer Center.

An active researcher, Dr. Lenz focuses on topics including the regulation of gene expression involved in drug resistance, patients at high risk of developing colorectal cancer, and determination of carcinogenesis, methods of early detection, and better surveillance of these cancers. He is a member of several professional societies, including the American Association for Cancer Research, the American Gastroenterology Association, and the National Society of Genetic Counselors. He also serves on the National Advisory Board of a number of professional organizations. Dr. Lenz is the author of numerous peer-reviewed publications and invited papers, reviews, and editorials. He also serves as Co-Chair of the GI Committee and Correlative Science Committee for SWOG. He is a member of the NCI Task Force for Gastroesophageal Cancer, the NCI Steering Committee and the NCI Translational Science Committee. In addition to having an NCI-funded laboratory, he was a recipient of the ASCO Young Investigator Award, the ASCO Career Development Award, and the STOP Cancer Career Development Award. He has been listed in the Best Doctors’ database (www.bestdoctors.com) since 2003.

As Associate Director for Clinical Research, Dr. Lenz oversees the programmatic activities of the Gastrointestinal Cancers, Genitourinary Cancers, Women’s Cancers, and Leukemia and Lymphoma Programs.
sc ctsi logoPowered by SC CTSI